Trial · NCT06828601
Perioperative Lidocaine Infusions for the Management of Pain From Burn Injury
NCT06828601, Phase 4, Not yet recruiting, University of Washington
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Perioperative Lidocaine Infusions for the Management of Pain From Burn Injury. Trials, record NCT06828601. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06828601
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Perioperative Lidocaine Infusions for the Management of Pain From Burn Injury
- NCT number
- NCT06828601
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 20 participants, estimated
- Lead sponsor
- University of Washington
- Conditions
- Pain Management, Burn Injury, Lidocaine
- Interventions
- IV Lidocaine, IV Saline
- First posted
- 2025-02-14
- Last updated
- 2025-04-04
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility of Study for future larger RCT-Recruitment | Through study completion, an average of 6 months | Recruitment rate (screening and recruitment of 20 patients over 6 months) |
| Primary | Feasibility of Study for future larger RCT-Preliminary Data | Through study completion, an average of 6 months | Review of preliminary data for calculation of a sample size, minimum number of subjects needed to enroll in a future RCT for adequate power. |
| Primary | Feasibility of Study for future larger RCT-Acceptability of Intervention | Through study completion, an average of 6 months | Review of randomization and blinding processes, including both patients and clinical provider's experience |
| Primary | Feasibility of Study for future larger RCT-Data collection | Through study completion, an average of 6 months | The suitability of the methods for data collection, which are In person visits at 24, 48 \& 72hr and likely phone/virtual follow-ups at 2 weeks and 3 months |
| Primary | Feasibility of Study for future larger RCT-Reliability of data | Through study completion, an average of 6 months | The reliability of data collected for analysis of analgesic efficacy includes review of numerical pain scores, total morphine equivalent dose (MED), Quality of Recovery Scores (QoR-15), and Brief Pain Inventory (BPI). Analgesic efficacy is expressed as the NNT, the number of patients who need to receive the active drug for one to achieve at least 50% pain relief compared with placebo over a 4-6h treatment period. |
| Primary | Feasibility of Study for future larger RCT-Outcomes | Through study completion, an average of 6 months | Review of current Secondary Outcome to determine if appropriate to become Primary Outcomes for future RCT |
| Primary | Feasibility of Study for future larger RCT-Complete Data collection | Through study completion, an average of 6 months | Determine completion rate of collected data |
| Secondary | Length of Hospital Stay | Up to 50 weeks | This is calculated from the date admitted to the hospital to the date of hospital discharge. |
| Secondary | Adverse effects of lidocaine infusion | 48 hours - During the lidocaine infusion | |
| Secondary | Total MED | MED assessed at 24-, 48-, and 72-hours post-operatively | MED=Morphine Equivalent Dose. MED are values that represent the potency of an opioid dose relative to morphine. MED equates the many different opioids into a standard value that is based on morphine and its potency. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06828601
GET https://conductscience.org/api/trials/v1/NCT06828601/registered